Study of Sleep-Wake Cycle Biomarkers and Their Role in Cognitive Decline in Mild Alzheimers Disease in Adults Aged 50 to 85

What this Trial Is About

Alzheimers disease AD is marked by a gradual loss of memory and thinking skills. Early in AD, certain molecules called beta-amyloid peptides build up in the brain. This study aims to explore if there is a connection between cognitive decline and sleep problems in people with mild Alzheimers disease. Discovering such a link may help in developing earlier treatments for sleep issues to possibly slow AD progression. Participants will undergo various assessments including 24-hour sleep studies polysomnography and actimetry to monitor activity over 14 days, both at the start and after 24 months. Neuropsychological testing and questionnaires about sleep and behavior will be done at the start, 12 months, and 24 months. Additional tests include measuring internal body temperature and analyzing biomarkers from blood and cerebrospinal fluid samples. During the study, participants will be monitored with sleep studies, cognitive tests, urine collection to measure melatonin, and biomarker assays to track changes over two years. Researchers will measure changes in memory and cognition using specific tests like the Free and Cued Selective Reminding Test. Safety and adherence will be checked throughout the 24-month participation period to better understand the role of sleep in cognitive decline.

Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?